Four different studies conducted in different ways examining different groups have linked use of certain psychiatric drugs to bone fracture risks and negative impacts on human bone development.
A new systematic review finds that patients report reduced symptoms but also loss of self and agency while taking antipsychotics.
In a featured article for Psychiatric Services, psychiatrists from Dartmouth raise the alarm on the increasing numbers of children prescribed dangerous antipsychotic drugs. Despite the fact that data on the safety of long-term use of these drugs in this vulnerable population “do not exist,” the rate of children and adolescents being prescribed antipsychotic drugs have continued to increase over the past fifteen years.
BBC news conducts a video interview with a young man named George. He was prescribed antidepressants when he was 15, after only a five-minute...
Increased Parkinson's risk could be related to lithium, antipsychotic, and antiepileptic drug use.
Researchers, Jon Jureidini, Jay Amsterdam and Leemon McHenry, have taken a closer look at the data from a randomized control trial of citalopram (Celexa) that was ghostwritten and then used by the manufacturers to support claims of the drug’s efficacy and safety in the treatment of child and adolescent depression. To get the background on this story, we connected with Dr. Leemon McHenry, an investigator in this study and a lecturer in philosophy at California State University, Northridge.
Stimulant medications like Ritalin and Adderall, often prescribed to treat children diagnosed with ADHD, are known to cause hallucinations and psychotic symptoms. Until recently these adverse effects were considered to be rare. A new study to be published in the January issue of Pediatrics challenges this belief, however, and finds that many more children may be experiencing psychotic symptoms as a result of these drugs than previously acknowledged.
Gepirone, a new depression drug by Fabre-Kramer Pharmaceuticals, did not meet the FDAs efficacy standards. The new drug application for gepirone has now received...
Researchers take action after study exposes enduring sexual dysfunction as a potential side effect of serotonin reuptake inhibiting antidepressants, 5α-reductase inhibitors, and isotretinoin.
John Ioannidis claims that the idea of evidence based medicine has been “hijacked to serve agendas different from what it was originally aimed for,” in a newly published critical essay in the Journal of Clinical Epidemiology. Ioannidis frames the essay as a continuation of a conversation with David Sackett, widely considered the founder of evidence based medicine.
In an open letter to all US presidential candidates published Thursday in the BMJ, a group of global health care experts assert that current research regulations allow drug companies to publish incomplete and misleading results. They ask the candidates to declare whether they support improved transparency measures that would make data on drug studies publically available and open to scrutiny.
New research counters the long-held assumption that a longer duration of untreated psychosis is associated with worse outcomes.
A new study has reinforced earlier warnings that taking SSRI antidepressants late in pregnancy appears to put mothers at a slightly increased risk of having newborns with persistent pulmonary hypertension.
Following an extensive systematic review of treatments for major depression, the American College of Physicians (ACP) issued a recommendation to clinicians suggesting cognitive behavioral therapy (CBT) as a first-line treatment for major depressive disorder along with second-generation antidepressants. The results of the review revealed that CBT and antidepressants have similar levels of effectiveness but that antidepressants present serious side-effects and higher relapse rates.
Antidepressant use during pregnancy has been associated with a number of fetal and developmental complications. The latest meta-analysis of the effect of SSRI antidepressants...
In a new article for Scientific American, Diana Kwon reports on how the true risks for suicide and aggression in children and teens taking...
The International Business Times covers a new study showing “trials for new antidepressant medications may not be applicable to the population at large.” “The finding, published in the Mayo Clinic Proceedings, shows recent trials are less generalizable than the prior studies, as researchers excluded most depressed patients from drug company-sponsored treatment studies.”
The results of the cross-sectional study show that U.S. Department of Veterans Affairs (VA) owned hospitals perform worst on most measures.
Researchers shed light on the precarious nature of evidence from efficacy trials of antidepressant medication to treat symptoms of major depressive disorder in children and adolescents.
A change.org petition out of the United Kingdom is addressing the extreme difficulty faced by people who attempt to taper off of antidepressants and...
Neuroscientists have just released the results of a study on the long-term use of antipsychotic drugs in children. The growing brain adapts to the...
Ethnographic research sheds light on extensive psychopharmaceutical use by soldiers in post 9/11 U.S. wars.
One-third of adults with an intellectual or developmental disability are dispensed antipsychotics, despite having no existing psychiatric diagnosis.
A “not otherwise specified” (NOS) diagnosis is often used when an individual may have some symptoms related to a psychiatric diagnosis but does not meet enough criteria to warrant a particular diagnosis. A new study, published online ahead of print in Psychiatric Services, reveals that the proportion of mental health visits resulting in such NOS diagnoses rose to nearly fifty percent, and that these diagnoses do not result in more conservative psychiatric drug prescriptions.
Writing for Forbes, Matthew Herper documents the FDA’s increasing drug approval rates. “In 2008, BioMedTracker says the FDA approved 20 new molecular entities (NMEs) and rejected 20, for an approval rate of 50%.” So far this year, he writes, “the FDA approval rate is more like 96%.”